IDM Pharma, Inc. today announced that the European Commission has formally granted a Centralized marketing authorization for MEPACT (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
The details can be read here.
No comments:
Post a Comment